Literature DB >> 17638867

HER4 D-box sequences regulate mitotic progression and degradation of the nuclear HER4 cleavage product s80HER4.

Karen E Strunk1, Carty Husted, Leah C Miraglia, Melissa Sandahl, William A Rearick, Debra M Hunter, H Shelton Earp, Rebecca S Muraoka-Cook.   

Abstract

Heregulin-mediated activation of HER4 initiates receptor cleavage (releasing an 80-kDa HER4 intracellular domain, s80(HER4), containing nuclear localization sequences) and results in G(2)-M delay by unknown signaling mechanisms. We report herein that s80(HER4) contains a functional cyclin B-like sequence known as a D-box, which targets proteins for degradation by anaphase-promoting complex (APC)/cyclosome, a multisubunit ubiquitin ligase. s80(HER4) ubiquitination and proteasomal degradation occurred during mitosis but not during S phase. Inhibition of an APC subunit (APC2) using short interfering RNA knockdown impaired s80(HER4) degradation. Mutation of the s80(HER4) D-box sequence stabilized s80(HER4) during mitosis, and s80(HER4)-dependent growth inhibition via G(2)-M delay was significantly greater with the D-box mutant. Polyomavirus middle T antigen-transformed HC11 cells expressing s80(HER4) resulted in smaller, less proliferative, more differentiated tumors in vivo than those expressing kinase-dead s80(HER4) or the empty vector. Cells expressing s80(HER4) with a disrupted D-box did not form tumors, instead forming differentiated ductal structures. These results suggest that cell cycle-dependent degradation of s80(HER4) limits its growth-inhibitory action, and stabilization of s80(HER4) enhances tumor suppression, thus providing a link between HER4-mediated growth inhibition and cell cycle control.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17638867      PMCID: PMC2917069          DOI: 10.1158/0008-5472.CAN-06-4145

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Role of the ErbB-4 carboxyl terminus in gamma-secretase cleavage.

Authors:  Chang-Yuan Ni; Hongping Yuan; Graham Carpenter
Journal:  J Biol Chem       Date:  2002-11-25       Impact factor: 5.157

2.  Ectodomain cleavage of ErbB-4: characterization of the cleavage site and m80 fragment.

Authors:  Qiu-Chen Cheng; Oleg Tikhomirov; Wenli Zhou; Graham Carpenter
Journal:  J Biol Chem       Date:  2003-07-16       Impact factor: 5.157

Review 3.  The anaphase-promoting complex: it's not just for mitosis any more.

Authors:  J Wade Harper; Janet L Burton; Mark J Solomon
Journal:  Genes Dev       Date:  2002-09-01       Impact factor: 11.361

4.  Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2.

Authors:  Shao-Chun Wang; Huang-Chun Lien; Weiya Xia; I-Fen Chen; Hui-Wen Lo; Zhiqin Wang; Mohamed Ali-Seyed; Dung-Fang Lee; Geoffrey Bartholomeusz; Fu Ou-Yang; Dipak K Giri; Mien-Chie Hung
Journal:  Cancer Cell       Date:  2004-09       Impact factor: 31.743

5.  Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.

Authors:  Caroline J Witton; Jonathan R Reeves; James J Going; Timothy G Cooke; John M S Bartlett
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

6.  Degradation of cyclin B is required for the onset of anaphase in Mammalian cells.

Authors:  Donald C Chang; Naihan Xu; Kathy Q Luo
Journal:  J Biol Chem       Date:  2003-07-14       Impact factor: 5.157

7.  Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5.

Authors:  Weiwen Long; Kay-Uwe Wagner; K C Kent Lloyd; Nadine Binart; Jonathan M Shillingford; Lothar Hennighausen; Frank E Jones
Journal:  Development       Date:  2003-09-03       Impact factor: 6.868

8.  WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus.

Authors:  Akihiko Komuro; Makoto Nagai; Nicholas E Navin; Marius Sudol
Journal:  J Biol Chem       Date:  2003-06-13       Impact factor: 5.157

9.  Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling.

Authors:  Sian M Tovey; Caroline J Witton; John M S Bartlett; Peter D Stanton; Jonathan R Reeves; Timothy G Cooke
Journal:  Breast Cancer Res       Date:  2004-03-23       Impact factor: 6.466

10.  Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.

Authors:  D M Abd El-Rehim; S E Pinder; C E Paish; J A Bell; R S Rampaul; R W Blamey; J F R Robertson; R I Nicholson; I O Ellis
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

View more
  6 in total

Review 1.  E3 ubiquitin ligases in ErbB receptor quantity control.

Authors:  Kermit L Carraway
Journal:  Semin Cell Dev Biol       Date:  2010-09-22       Impact factor: 7.727

Review 2.  HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer.

Authors:  Frank E Jones
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-13       Impact factor: 2.673

3.  ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo.

Authors:  Rebecca S Muraoka-Cook; Melissa A Sandahl; Karen E Strunk; Leah C Miraglia; Carty Husted; Debra M Hunter; Klaus Elenius; Lewis A Chodosh; H Shelton Earp
Journal:  Mol Cell Biol       Date:  2009-07-13       Impact factor: 4.272

4.  The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation.

Authors:  Shu-Mang Feng; Rebecca S Muraoka-Cook; Debra Hunter; Melissa A Sandahl; Laura S Caskey; Keiji Miyazawa; Azeddine Atfi; H Shelton Earp
Journal:  Mol Cell Biol       Date:  2008-12-01       Impact factor: 4.272

Review 5.  ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition.

Authors:  Rebecca S Muraoka-Cook; Shu-Mang Feng; Karen E Strunk; H Shelton Earp
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-04-25       Impact factor: 2.673

6.  HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.

Authors:  Anthony Kong; Véronique Calleja; Pierre Leboucher; Adrian Harris; Peter J Parker; Banafshé Larijani
Journal:  PLoS One       Date:  2008-08-06       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.